Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06533553
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-30
Brief Title:
A Study to Assess the Effects of Dexpramipexole in Participants with Eosinophilic COPD
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-label Phase II Study to Assess the Pharmacodynamic PD Effects of Dexpramipexole in Participants with Eosinophilic Chronic Obstructive Pulmonary Disease COPD
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SUSPIRE-1
Brief Summary:
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily BID in participants with eosinophilic COPD This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts AEC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None